March 13, 2025 · Phase 2 readout
ATXS Phase 2 readout: a partial negative outcome, -7.0%
On March 13, 2025, STAR-0215 — Astria Therapeutics, Inc. (Hereditary Angioedema) reached its Phase 2 readout. The result was a partial negative outcome, and the stock moved -7.0% in the window around the event. It had already run -14.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$7.14
1d before
$6.64
Event day
$6.45
1d after
$6.49
5d after
Pre-catalyst setup
-14.9%
30-day run-up
6723%
30-day volatility